[
    [
        {
            "time": "2019-06-30",
            "original_text": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业增速",
                    "龙头引领",
                    "创新药产业链",
                    "创新生物制品",
                    "医疗服务"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品",
                    "医疗服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-09-01",
            "original_text": "医药生物9月投资逻辑：核心资产仍为投资方向，优选业绩增长加速或估值合理标的",
            "features": {
                "keywords": [
                    "医药生物",
                    "核心资产",
                    "业绩增长",
                    "估值合理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物9月投资逻辑：核心资产仍为投资方向，优选业绩增长加速或估值合理标的",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-31",
            "original_text": "【医药】医药生物行业2019年中报综述: 板块内部继续分化，2019全年业绩前低后高*强于大市",
            "features": {
                "keywords": [
                    "医药生物",
                    "板块分化",
                    "全年业绩",
                    "前低后高"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】医药生物行业2019年中报综述: 板块内部继续分化，2019全年业绩前低后高*强于大市",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-06-30",
            "original_text": "医药行业2019年半年报总结: 业绩与行情分化持续, 强者恒强",
            "features": {
                "keywords": [
                    "医药行业",
                    "业绩分化",
                    "强者恒强"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2019年半年报总结: 业绩与行情分化持续, 强者恒强",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-06-30",
            "original_text": "华兰生物: 血制品持续回暖, 看好疫苗业绩弹性",
            "features": {
                "keywords": [
                    "华兰生物",
                    "血制品",
                    "疫苗",
                    "业绩弹性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物: 血制品持续回暖, 看好疫苗业绩弹性",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-06-30",
            "original_text": "华兰生物: 疫苗业务有所拖累, 下半年有望恢复高增长",
            "features": {
                "keywords": [
                    "华兰生物",
                    "疫苗业务",
                    "下半年",
                    "高增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物: 疫苗业务有所拖累, 下半年有望恢复高增长",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-06-30",
            "original_text": "华兰生物: 静丙销售改善推动血制品恢复, 下半年疫苗放量可期",
            "features": {
                "keywords": [
                    "华兰生物",
                    "静丙",
                    "血制品",
                    "疫苗",
                    "放量"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物: 静丙销售改善推动血制品恢复, 下半年疫苗放量可期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-06-30",
            "original_text": "华兰生物: 静丙拉动血制品高速增长, 下半年疫苗进入销售旺季",
            "features": {
                "keywords": [
                    "华兰生物",
                    "静丙",
                    "血制品",
                    "疫苗",
                    "销售旺季"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华兰生物: 静丙拉动血制品高速增长, 下半年疫苗进入销售旺季",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]